Abstract Library

#2982 Comprehensive Molecular Analysis Identifies Driver Mutations in Metastases of Sporadic Well-Differentiated Neuroendocrine Tumours of the Small Intestine

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) represent a heterogenous group of tumours. The molecular mechanisms which contribute to progression of SI-NETs are poorly elucidated. They are considered to be molecularly distinct from neuroendocrine carcinomas (NECs), which share oncogenic pathways with adenocarcinomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Samsom K

Authors: Samsom K, van Veenendaal L, Roepman P, Kodach L, Steeghs N,

Keywords: whole genome sequencing, neuroendocrine tumour, small intestine, genetics,

#2965 Molecular Signature of Rectal Neuroendocrine Neoplasia

Introduction: Rectal neuroendocrine tumors are rare neuroendocrine neoplasias (NEN). Little is known about prevalence and type of somatostatin receptor subtypes (sstr) expression and somatic mutations in relation to long-term clinical outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Unger N, Theurer S, Herold T, Weber F, Dralle H,

Keywords: Somatic Mutations, NGS, Somatostatin receptor subtypes, Intestinal NEN,

#2920 Mutation Spectrums Analysis of Colorectal Adenocarcinoma and Neuroendocrine Neoplasm Based on Same Genetic Background to Reveal Tumorigenesis

Introduction: The tumorigenesis of neuroendocrine neoplasm (NEN) are still ambiguous. The therapies of NENs in colon or rectum refer to adenocarcinomas (AC) when tumor metastasis, but the response was unsatisfactory which inspired us to explore the mutation difference.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hu H

Authors: Cai W, Ge W, Wu D, Mao J, Hu H,

Keywords: Neuroendocrine neoplasm, Tumorigenesis, Mutation spectrums, Colorectal,

#2795 Molecular Correlation of the Activity of Evofosfamide (EVO) in Combination with Sunitinib (SUN) in Pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial

Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Santos M, Lanillos J, Lopez C, Alonso Gordoa T, Benavent M,

Keywords: pancreatic, neuroendocrine, mutations, correlation,

#2108 Molecular Characterization of Primary and Metastatic Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumours (PNETs) are a heterogeneous group of rare pancreatic neoplasms often diagnosed with distant metastases, which are associated with significantly poorer prognosis. Recurrent somatic mutations, chromosomal aberrations and gene expression signatures in PNETs have been described, but the clinical significance of these molecular changes is still poorly understood, and the clinical outcomes of PNET patients remain highly variable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yang K, Wong H, Shen Y, Colborne S, Kalloger S,

Keywords: pancreatic neuroendocrine tumor, metastasis, primary tumor, proteomics, transcriptomics,